GENEVA, & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of selective NOX inhibitors, today announced that the Company will present at the 17th Annual BIO CEO and Investor Conference in New York City. Ursula Ney, Genkyotex's chief executive officer, will deliver a corporate and NOX inhibitor pipeline overview on Tuesday, February 10th at 11:30 a.m. ET. The presentation will take place in the Park South room at the Waldorf Astoria.
Genkyotex is unlocking the potential of selective NOX enzyme inhibition to discover and develop a pipeline of drugs for hard to treat chronic diseases. For further information please visit www.genkyotex.com